Isoform-Selective Histone Deacetylase Inhibitors

Author(s): Takayoshi Suzuki, Yukihiro Itoh, Naoki Miyata.

Journal Name: Current Pharmaceutical Design

Volume 14 , Issue 6 , 2008

Become EABM
Become Reviewer


Histone deacetylases (HDACs) catalyze the deacetylation of the acetylated lysine residues of histones and non-histone proteins, and are involved in various fundamental life phenomena, such as gene expression and cell cycle progression. Thus far, eighteen HDAC family members have been identified and they can be divided into two categories, i.e., zinc-dependent enzymes (HDAC1-11) and NAD+-dependent enzymes (SIRT1-7). Some of the HDAC isoforms have important roles in cell functions, and are associated with various disease states, including cancer. Therefore, isoform-selective HDAC inhibitors are of great interest, not only as tools for probing the biological functions of the isoforms, but also as candidate therapeutic agents with few side effects. In this review, we cover isoformselective HDAC inhibitors, including their biochemical and pharmacological functions.

Keywords: Histone deacetylase, HDAC inhibitors, SIRT inhibitors, isoform-selective inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [529 - 544]
Pages: 16
DOI: 10.2174/138161208783885335
Price: $58

Article Metrics

PDF: 18